A Secure Group Communication Architecture for Autonomous Unmanned Aerial Vehicle

This paper investigates the application of a secure group communication architecture to a swarm of autonomous unmanned aerial vehicles (UAVs). A multicast secure group communication architecture for the low earth orbit (LEO) satellite environment is evaluated to determine if it can be effectively adapted to a swarm of UAVs and provide secure, scalable, and efficient communications. The performance of the proposed security architecture is evaluated with two other commonly used architectures using a discrete event computer simulation developed using MATLAB. Performance is evaluated in terms of the scalability and efficiency of the group key distribution and management scheme when the swarm size, swarm mobility, multicast group join and departure rates are varied. The metrics include the total keys distributed over the simulation period, the average number of times an individual UAV must rekey, the average bandwidth used to rekey the swarm, and the average percentage of battery consumed by a UAV to rekey over the simulation period. The proposed security architecture can successfully be applied to a swarm of autonomous UAVs using current technology. The proposed architecture is more efficient and scalable than the other tested and commonly used architectures. Over all the tested configurations, the proposed architecture distributes 55.2–94.8% fewer keys, rekeys 59.0–94.9% less often per UAV, uses 55.2–87.9% less bandwidth to rekey, and reduces the battery consumption by 16.9–85.4%

A Secure Group Communication Architecture for Autonomous Unmanned Aerial Vehicles

This paper investigates the application of a secure group communication architecture to a swarm of autonomous unmanned aerial vehicles (UAVs). A multicast secure group communication architecture for the low earth orbit (LEO) satellite environment is evaluated to determine if it can be effectively adapted to a swarm of UAVs and provide secure, scalable, and efficient communications. The performance of the proposed security architecture is evaluated with two other commonly used architectures using a discrete event computer simulation developed using MATLAB. Performance is evaluated in terms of the scalability and efficiency of the group key distribution and management scheme when the swarm size, swarm mobility, multicast group join and departure rates are varied. The metrics include the total keys distributed over the simulation period, the average number of times an individual UAV must rekey, the average bandwidth used to rekey the swarm, and the average percentage of battery consumed by a UAV to rekey over the simulation period. The proposed security architecture can successfully be applied to a swarm of autonomous UAVs using current technology. The proposed architecture is more efficient and scalable than the other tested and commonly used architectures. Over all the tested configurations, the proposed architecture distributes 55.2–94.8% fewer keys, rekeys 59.0–94.9% less often per UAV, uses 55.2–87.9% less bandwidth to rekey, and reduces the battery consumption by 16.9–85.4%

The Thermal Properties of Solar Flares Over Three Solar Cycles Using GOES X-ray Observations

Solar flare X-ray emission results from rapidly increasing temperatures and emission measures in flaring active region loops. To date, observations from the X-Ray Sensor (XRS) onboard the Geostationary Operational Environmental Satellite (GOES) have been used to derive these properties, but have been limited by a number of factors, including the lack of a consistent background subtraction method capable of being automatically applied to large numbers of flares. In this paper, we describe an automated temperature and emission measure-based background subtraction method (TEBBS), which builds on the methods of Bornmann (1990). Our algorithm ensures that the derived temperature is always greater than the instrumental limit and the pre-flare background temperature, and that the temperature and emission measure are increasing during the flare rise phase. Additionally, TEBBS utilizes the improved estimates of GOES temperatures and emission measures from White et al. (2005). TEBBS was successfully applied to over 50,000 solar flares occurring over nearly three solar cycles (1980-2007), and used to create an extensive catalog of the solar flare thermal properties. We confirm that the peak emission measure and total radiative losses scale with background subtracted GOES X-ray flux as power-laws, while the peak temperature scales logarithmically. As expected, the peak emission measure shows an increasing trend with peak temperature, although the total radiative losses do not. While these results are comparable to previous studies, we find that flares of a given GOES class have lower peak temperatures and higher peak emission measures than previously reported. The resulting TEBBS database of thermal flare plasma properties is publicly available on Solar Monitor (www.solarmonitor.org/TEBBS/) and will be available on Heliophysics Integrated Observatory (www.helio-vo.eu)

Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring

Objectives: The resistance profiles of patients receiving long-term ART in sub-Saharan Africa have been poorly described. This study obtained a sensitive assessment of the resistance patterns associated with long-term tenofovir-based ART in a programmatic setting where virological monitoring is yet to become part of routine care. Methods: We studied subjects who, after a median of 4.2 years of ART, replaced zidovudine or stavudine with tenofovir disoproxil fumarate while continuing lamivudine and an NNRTI. Using deep sequencing, resistance-associated mutations (RAMs) were detected in stored samples collected at tenofovir introduction (T0) and after a median of 4.0 years (T1). Results: At T0, 19/87 (21.8%) subjects showed a detectable viral load and 8/87 (9.2%) had one or more major NNRTI RAMs, whereas 82/87 (94.3%) retained full tenofovir susceptibility. At T1, 79/87 (90.8%) subjects remained on NNRTI-based ART, 5/87 (5.7%) had introduced lopinavir/ritonavir due to immunological failure, and 3/87 (3.4%) had interrupted ART. Whilst 68/87 (78.2%) subjects maintained or achieved virological suppression between T0 and T1, a detectable viral load with NNRTI RAMs at T0 predicted lack of virological suppression at T1. Each treatment interruption, usually reflecting unavailability of the dispensary, doubled the risk of T1 viraemia. Tenofovir, lamivudine and efavirenz selected for K65R, K70E/T, L74I/V and Y115F, alongside M184V and multiple NNRTI RAMs; this resistance profile was accompanied by high viral loads and low CD4 cell counts. Conclusions: Viraemia on tenofovir, lamivudine and efavirenz led to complex resistance patterns with implications for continued drug activity and risk of onward transmission

Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation.

BackgroundWell-differentiated thyroid cancer (WDTC) incidence in pediatrics is rising, most being papillary thyroid carcinoma (PTC). The objective of the study was to assess the prevalence of different mutations in pediatric WDTC and correlate the genotype with the clinical phenotype.MethodsThis is a single-center retrospective study. Thyroid tissue blocks from 42 consecutive pediatric WDTC patients who underwent thyroidectomy between 2001 and 2013 were analyzed at Quest Diagnostics for BRAF(V600E), RAS mutations (N,K,H), and RET/PTC and PAX8/PPARγ rearrangements, using validated molecular methods. Thyroid carcinomas included PTC, follicular thyroid carcinoma (FTC), and follicular variant of PTC (FVPTC).ResultsThirty-nine samples (29 females) were genotyped. The mean age at diagnosis was 14.7 years (range 7.9-18.4 years), and most were Hispanic (56.4%) or Caucasian (35.9%). The mean follow-up period was 2.9 years. Mutations were noted in 21/39 (53.8%), with both BRAF(V600E) (n = 9), and RET/PTC (n = 6) detected only in PTC. Mutations were detected in 2/5 FTC (PAX8/PPARγ and NRAS) and 3/6 FVPTC cases (PAX8/PPARγ). Of 28 PTC patients, 57.1% had mutations: 32.1% with BRAF(V600E), 21.4% with RET/PTC, and 3.6% with NRAS. Of patients with BRAF(V600E), 77.8% were Hispanic and 88.9% were >15 years, while all RET/PTC-positive patients were ≤15 years (p = 0.003). Tumor size, lymph node involvement, and distant metastasis at diagnosis (or soon after (131)I ablation) did not vary significantly based on the mutation.ConclusionsBRAF(V600E) was the most common mutation, especially in older and Hispanic adolescents. A larger, ethnically diverse pediatric cohort followed long term will enable the genotypic variability, clinical presentation, and response to therapy to be better assessed

Pharmacologic management of Mycobacterium ulcerans infection

Introduction: Pharmacological treatment of Buruli ulcer (Mycobacterium ulcerans infection; BU) is highly effective, as shown in two randomized trials in Africa. Areas covered: We review BU drug treatment–in vitro, in vivo and clinical trials (PubMed: ‘(Buruli OR (Mycobacterium AND ulcerans)) AND (treatment OR therapy).’ We also highlight the pathogenesis of M. ulcerans infection that is dominated by mycolactone, a secreted exotoxin, that causes skin and soft tissue necrosis, and impaired immune response and tissue repair. Healing is slow, due to the delayed wash-out of mycolactone. An array of repurposed tuberculosis and leprosy drugs appears effective in vitro and in animal models. In clinical trials and observational studies, only rifamycins (notably, rifampicin), macrolides (notably, clarithromycin), aminoglycosides (notably, streptomycin) and fluoroquinolones (notably, moxifloxacin, and ciprofloxacin) have been tested. Expert opinion: A combination of rifampicin and clarithromycin is highly effective but lesions still take a long time to heal. Novel drugs like telacebec have the potential to reduce treatment duration but this drug may remain unaffordable in low-resourced settings. Research should address ulcer treatment in general; essays to measure mycolactone over time hold promise to use as a readout for studies to compare drug treatment schedules for larger lesions of Buruli ulcer

Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening

Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by the degeneration of alpha motor neurons in the spinal cord, leading to muscular atrophy. SMA is caused by deletions or mutations in the survival motor neuron 1 gene (SMN1). In humans, a nearly identical copy gene, SMN2, is present. Because SMN2 has been shown to decrease disease severity in a dose-dependent manner, SMN2 copy number is predictive of disease severity. To develop a treatment algorithm for SMA-positive infants identified through newborn screening based upon SMN2 copy number. A working group comprised of 15 SMA experts participated in a modified Delphi process, moderated by a neutral third-party expert, to develop treatment guidelines. The overarching recommendation is that all infants with two or three copies of SMN2 should receive immediate treatment (n = 13). For those infants in which immediate treatment is not recommended, guidelines were developed that outline the timing and appropriate screens and tests to be used to determine the timing of treatment initiation. The identification SMA affected infants via newborn screening presents an unprecedented opportunity for achievement of maximal therapeutic benefit through the administration of treatment pre-symptomatically. The recommendations provided here are intended to help formulate treatment guidelines for infants who test positive during the newborn screening process

Cardiovascular and renal outcomes following percutaneous coronary intervention in a population with renal disease: a case-control study

Background Patients with renal disease are less likely to undergo percutaneous coronary intervention (PCI) due to concerns about poor outcomes. Aim We describe outcomes following PCI in individuals with chronic kidney disease (CKD), as compared with matched controls with comparable CKD who did not undergo PCI. We also identified factors predictive of poor outcomes following PCI amongst patients with CKD. Design Retrospective observational case-control study. Methods Cases were individuals with CKD (stages 1–5) undergoing PCI between 2008 and 2014. Controls were age, gender and creatinine-matched individuals not requiring PCI. We compared mortality between groups using Kaplan–Meier curves and Cox regression modelling. We assessed changes in serum creatinine using Wilcoxon Rank testing. We explored the relationship between biochemical and haematological measures (baseline creatinine, calcium, phosphate, calcium-phosphate product, parathyroid hormone, white cell count, haemoglobin, platelet count, c-reactive protein and total cholesterol) and post-PCI mortality, using logistic regression. Results We identified 144 cases and 144 controls. Mortality was significantly lower amongst cases compared with controls [hazard ratio 0.46 (95% confidence intervals 0.31, 0.69)]. PCI did not result in a significant change in renal function (P=0.52). Amongst cases, serum creatinine and calcium-phosphate product were predictors of mortality following PCI. Conclusion Cases undergoing PCI had lower mortality, and PCI was not associated with accelerated CKD progression. On this data, PCI should not be deferred as a treatment option in patients with CKD. Serum creatinine and calcium-phosphate product predict mortality following PCI in this cohort, and may be useful in risk-stratifying patients with CKD being considered for PCI